Aprepitant
- Generic Name
- Aprepitant
- Brand Names
- Aponvie, Cinvanti, Emend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21F7N4O3
- CAS Number
- 170729-80-3
- Unique Ingredient Identifier
- 1NF15YR6UY
- Background
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substan...
- Indication
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Post Operative Nausea and Vomiting (PONV), Acute delayed Nausea caused by highly emetogenic cancer chemotherapy
- Associated Therapies
- -
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00651755
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Multi-day Doses in Prevention of Nausea and Emesis
- Conditions
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00600353
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2008-01-09
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00588835
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
🇳🇱Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 69
- Registration Number
- NCT00572572
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Siteman Cancer Center, St. Louis, Missouri, United States
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2013-04-02
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT00499668
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Joseph Roscoe
- Target Recruit Count
- 1021
- Registration Number
- NCT00475085
- Locations
- 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸CCOP - Kalamazoo, Kalamazoo, Michigan, United States
Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Radboud University Medical Center
- Registration Number
- NCT00429754
Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 30
- Registration Number
- NCT00428519
- Locations
- 🇺🇸
Clinical Trials Unit. University of Pennsylvania, Philadelphia, Pennsylvania, United States
AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
- Conditions
- Interventions
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 196
- Registration Number
- NCT00415103
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital Universitario Marqués de Valdecilla, Santander, Spain
🇪🇸Hospital Universitario la Princesa, Madrid, Spain
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT00381862
- Locations
- 🇺🇸
St. Josephs/Cander Hospital, Savannah, Georgia, United States
🇺🇸Kaiser Permanente, Hilo, Hawaii, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.